Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARomatherapy for Cognitive Trajectory in Chinese After Coronary Artery Bypass Grafting (ARCTIC-CABG): a Randomized, Double-blind, Placebo-controlled Trial

NCT04102696 is registered in ClinicalTrials.gov with Beijing Anzhen Hospital as lead sponsor.

NCT NCT04102696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04102696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARomatherapy for Cognitive Trajectory in Chinese After Coronary Artery Bypass Grafting (ARCTIC-CABG): a Randomized, Double-blind, Placebo-controlled Trial
Lead sponsor
Beijing Anzhen Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
December 31, 2019
Completion date
June 30, 2021
Enrollment
460 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery bypass grafting, myocardial infarction